Cancer Biopsy Market Size, Share & Trends Analysis Report By Product (Instruments, Kits and Consumables, Services), By Type (Tissue Biopsies, Needle Biopsies {Fine Needle Aspiration [FNA] and Core Needle Biopsy [CNB]} and Surgical Biopsies), Liquid Biopsies, Others), By Applications (Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Skin Cancers, Blood Cancers, Kidney Cancers, Liver Cancers, Pancreatic Cancers, Ovarian Cancers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Cancer Biopsy Market Size

The global cancer biopsy market size was valued at USD 33.38 billion in 2025 and is projected to grow from USD 35.99 billion in 2026 to USD 65.68 billion by 2034, registering a CAGR of 7.81% during the forecast period from 2026 to 2034. North America dominated the cancer biopsy market with a market share of 41.2% in 2025.

The growing global geriatric population and resulting surge in cancer incidences, particularly breast cancer, are fueling the demand for biopsy devices.

A biopsy involves removing a small amount of tissue for observation under the microscope, whereas in a core biopsy, radiologists use a needle to remove a sample from the lung tumor for diagnosis. The healthcare provider often uses a chest CT scan or a special X-ray machine to guide the needle in this technique. Research studies have concluded that CT-guided core needle biopsies are a relatively safer and well-established technique for procuring tumor samples with a better yield than conventional biopsies, especially for screening EGFR mutations.

A biopsy is the process of removing tissue to examine it for disease. Tissue samples can be taken from any part of the body. Numerous techniques can be used to perform biopsies. Some biopsies include surgically removing a nodule or lump, while others involve removing a tiny sample of tissue using a needle. Despite their usefulness in detecting abnormalities, imaging tests like MRI and CT scans cannot tell the difference between cancerous and non-cancerous cells. The majority of cancers can only be identified by performing a biopsy and collecting cells for further analysis.

Product Insights

Based on product, the global market is segmented into instruments, kits and consumables, and services. The kits and consumables segment dominates the global market and is estimated to grow at a CAGR of 10.6% during the forecast period. Rapid transition from tumor biopsies to liquid biopsies is anticipated to propel the adoption of consumables and kits in various cancer biopsy procedures. Several industry players recognize this trend and are investing in developing next-generation cancer biopsy kits to diversify their offerings.

• For instance, Biocept, Inc. recently introduced a liquid biopsy kit developed for research applications related to cancer gene mutations. This launch was targeted to make the company's proprietary Target Selector platform of circulating tumor DNA assays accessible to molecular laboratories worldwide; these assays are used for performing liquid biopsies.

Request Customizationto receive a tailored report.

Type Insights

Based on type, the global market is categorized into tissue biopsies, needle biopsies {Fine Needle Aspiration [FNA] and Core Needle Biopsy [CNB]} and Surgical Biopsies), liquid biopsies, and others. The tissue biopsies segment owns the highest market share and is expected to exhibit a CAGR of 10.22% during the forecast period. Tissue biopsy is still considered the mainstay for cancer biopsies and is largely adopted in several cancer diagnostic applications. This can be attributed to robust research activities evaluating its safety and efficacy, which is anticipated to contribute to the segment's dominance in the global market over the forecast period. Liquid biopsies have the potential to completely transform the field of cancer diagnosis, but physicians and medical professionals in developing nations are only slowly embracing this innovative method. Moreover, enhancements to tissue biopsy procedures would maintain their position as industry leaders in acceptance over the next few years.

• For instance, Cernostics is creating a tissue biopsy test ideal for identifying cancer patients with Barrett's esophagus. Digitally scanned biopsy images from this one-of-a-kind cancer diagnostic test are used to analyze and quantify changes emerging at the cellular or molecular levels within a tissue.

Application Insights

Based on application, the global market is categorized into breast cancer, colorectal cancer, prostate cancer, skin cancer, kidney cancer, liver cancer, pancreatic cancer, ovarian cancer, and others. The breast cancer segment dominates the global market and is expected to grow at a CAGR of 12.6% during the forecast period. Open surgical biopsy has been a reference standard in evaluating patients who present abnormal breast lesions; this can be attributed to the proven accuracy in diagnosing breast lesions. A rising number of patients suspected to suffer from cancer are recommended to undergo microscope-based analysis of breast tissue, which helps doctors decide on a definitive diagnosis and detect the disease's stage and characterization. This has propelled the demand for a needle or surgical biopsy to gain tissue for microscopic examination.

Additionally, image-guided needle biopsy has emerged as an accurate and safe nonsurgical approach for detecting suspicious tissues in breast imaging; these yield findings integral for designing apt therapeutic methods. Percutaneous image-guided needle biopsy is gaining demand in effectively managing abnormal breast lesions, which is further expected to contribute to the segment's growth. Moreover, various manufacturers operate in this space, working toward introducing comprehensive biopsy systems designed specifically for breast cancer.

• For instance, Trivitron Healthcare offers Upright Stereotactic System and MultiCare Platinum breast biopsy prone table; the latter is designed to characterize lesions that are difficult to detect.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global market shareholder and is expected to expand substantially during the forecast period. Due to the substantial contribution of the U.S., the region is anticipated to sustain its dominant position throughout the forecast period. The primary objectives of companies in this region are to distribute and develop novel kits with applications for rapid diagnostics. Moreover, the lucrative strategies specified by the pertinent government authorities have significantly supported the increasing adoption of liquid biopsies across the United States. The framework, created recently by the U.S. Food and Drug Administration (FDA), is the foundation for liquid biopsy-based oncology diagnostics regulatory initiatives. This framework comprises the rules governing enrichment biomarkers, companion diagnostics, and approval precedents. The FDA's approval of tests created under the Clinical Laboratory Improvement Amendment has added value to the regulatory paths for liquid biopsy.

Unlock Regional Insightsto access country-level data, & regional trends.

List of Key and Emerging Players in Cancer Biopsy Market